Administrative Supplement (NoD)

行政补充（NoD）

• 批准号: 9986305
• 负责人: Kenneth Cusi
• 金额: $ 12.78万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9986305
• 关键词: Academic Medical Centers; Administrative Supplement; American; Area; Biological Markers; Biology; Chronic; Clinical; Clinical Research; Collaborations; Complications of Diabetes Mellitus; Cross-Sectional Studies; Cystic Fibrosis Transmembrane Conductance Regulator; Data; Development; Diabetes Mellitus; Diagnostic; Disease; Disease Outcome; Dyslipidemias; Endocrinology; Event; Florida; Frequencies; Funding; Gastroenterology; Genes; Genomics; Glucagon; Heterogeneity; Hyperglycemia; Incidence; Inflammatory; Insulin; Insulin Resistance; Insulin deficiency; Knowledge; Lead; Learning; Link; Malignant Neoplasms; Malignant neoplasm of pancreas; Metabolic; Non-Insulin-Dependent Diabetes Mellitus; Operative Surgical Procedures; Outcome; Pancreas; Pancreatitis; Patients; Process; Productivity; Prognostic Marker; Protocols documentation; Quality of life; Research; Research Infrastructure; Research Personnel; Resources; Risk; Risk Factors; Role; Sampling; Source; Specimen; Translational Research; United States National Institutes of Health; Universities; Variant; Work; acute pancreatitis; biobank; biomedical referral center; chronic pain; chronic pancreatitis; chymotrypsinogen C; cohort; diabetes mellitus genetics; diabetic; effective therapy; genetic risk factor; genetic variant; individualized medicine; inflammatory milieu; interest; metabolic profile; metabolomics; mortality; new therapeutic target; outcome prediction; patient subsets; profiles in patients; prognostic; public health relevance; research study; success; treatment effect; treatment risk

 DESCRIPTION (provided by applicant): The NIH has allocated funds for the establishment of a consortium of academic medical centers to use this collective to discover new underlying mechanisms that link pancreatitis, pancreatic cancer, and diabetes. The University of Florida is perfectly poised to contribute to this consortium. The UFHealth academic medical center has been a regional resource for these diseases for decades, resulting in high clinical volumes. Extensive expertise and translational research infrastructure are already in place. In this application, we demonstrate sustained productivity in the accrual of patients into research studies, high rates of procurement of relevant biospecimens in collaboration with our CTSI biorepository, and independent research efforts into these diseases that anchor our passion to contribute to the consortium. This application also represents an opportunity for increased collaboration between the clinical groups that represent the 3 portals of entry of patients with pancreatitis, diabetes, and pancreatic cancer; the Divisions of Gastroenterology (C. Forsmark, PD/PI), Endocrinology (K. Cusi, PD/PI), and General Surgery (S. Hughes, PD/PI). These investigators, who administratively lead their respective divisions, also represent an alignment of expertise in the diseases of interest (C. Forsmark, pancreatitis; K. Cusi, diabetes, and S. Hughes, pancreatic cancer). Specific Aim 1: To characterize the metabolic profile of patients with coexistent chronic pancreatitis and diabetes mellitus, and establish the role of the underlying metabolic profile, and the effect of treatment, to clinical outcomes. Specific Aim 2: To identify the longitudinal relationship(s) between known genomic variants of genes associated with pancreatitis and disease outcome. Specific Aim 3: To determine how the local inflammatory milieu in chronic pancreatitis and pancreatic cancer is related to disease specific outcomes and the development of diabetes. In summary, this proposed work spans critical areas of knowledge deficit: the role of metabolic profiles/diabetes subtypes to long-term outcomes, metabolomics of Type3c diabetes, genetic mechanisms leading to chronic pancreatitis and possibly pancreatic cancer, and the inflammatory state - both systemic and localized within the pancreas as a potential source of mechanistic contribution to the observed relationships between pancreatitis, pancreatic cancer, and diabetes, diagnostic/prognostic biomarkers and novel therapeutic targets.

 描述（由申请人提供）：美国国立卫生研究院已拨款建立一个学术医学中心联盟，利用这个集体来发现胰腺炎，胰腺癌和糖尿病之间的新的潜在机制。佛罗里达大学完全准备好为这个财团做出贡献。UFHealth学术医疗中心几十年来一直是这些疾病的区域资源，导致了高临床量。广泛的专业知识和转化研究基础设施已经到位。在这一应用中，我们证明了持续的生产力，在增加患者进入研究研究，高采购率的相关生物标本与我们的CTSI生物储存库，以及独立的研究工作，这些疾病的锚我们的热情，以促进财团。该应用程序还代表了临床组之间增加合作的机会，这些临床组代表了胰腺炎、糖尿病和胰腺癌患者的3个入口;胃肠病科（C。Forsmark，PD/PI），内分泌学（K. Cusi，PD/PI）和普通外科（S. Hughes，PD/PI）。这些调查员在行政上领导各自的司，也代表了联合国各机构的协调一致。 感兴趣的疾病的专业知识（C。Forsmark，胰腺炎; K. Cusi、糖尿病和S. Hughes，胰腺癌）。具体目标1：描述慢性胰腺炎和糖尿病并存患者的代谢特征，并确定基础代谢特征和治疗效果对临床结局的作用。具体目标2： 确定胰腺炎相关基因的已知基因组变异与疾病结果之间的纵向关系。具体目标3：确定慢性胰腺炎和胰腺癌的局部炎症环境与疾病特异性结局和糖尿病发展的关系。总之，这项拟议的工作涉及知识不足的关键领域：代谢谱/糖尿病亚型对长期结果的作用，3c型糖尿病的代谢组学，导致慢性胰腺炎和可能的胰腺癌的遗传机制，以及炎症状态-全身性和胰腺内局部性的炎症状态，作为胰腺炎，胰腺癌，和糖尿病，诊断/预后生物标志物和新的治疗靶点。